Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase - Time to Buy?

Key Points

• Nanobiotix shares traded at $38.15 with volume surging 166% to approximately 201,869 shares, compared with 75,912 shares in the prior session.
• Analyst sentiment is mixed but leans positive: four analysts rate the stock Buy, one rates it Hold and one Sell. The consensus is “Moderate Buy,” with an average price target of $37.33.
• Institutional ownership stands at 38.81%, with Millennium Management and Marshall Wace initiating positions and Royal Bank of Canada increasing its holdings. Nanobiotix is developing NBTXR3, a cancer-treatment radioenhancer that has CE Mark approval in Europe for soft tissue sarcoma.

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report) shares saw unusually-strong trading volume on Friday . Approximately 201,869 shares changed hands during mid-day trading, an increase of 166% from the previous session's volume of 75,912 shares.The stock last traded at $38.15 and had previously closed at $38.17.

Analyst Ratings Changes

Several equities analysts recently issued reports on NBTX shares. UBS Group boosted their price target on Nanobiotix from $3.50 to $30.00 and gave the company a "neutral" rating in a research note on Friday, May 1st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nanobiotix in a research report on Friday, July 17th. Leerink Partners lifted their price objective on Nanobiotix from $37.00 to $46.00 and gave the stock an "outperform" rating in a report on Thursday, June 4th. Finally, HC Wainwright restated a "buy" rating on shares of Nanobiotix in a research report on Monday, May 18th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $37.33.

Nanobiotix Trading Up 0.0%

The firm's fifty day moving average is $37.76 and its 200-day moving average is $34.59.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of NBTX. Millennium Management LLC bought a new position in Nanobiotix in the 4th quarter valued at $390,000. Marshall Wace LLP acquired a new position in Nanobiotix in the fourth quarter worth $220,000. Finally, Royal Bank of Canada grew its holdings in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company's stock worth $61,000 after purchasing an additional 2,500 shares during the last quarter. 38.81% of the stock is owned by institutional investors and hedge funds.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company's lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source